Cellebrite DI Share Price Today

Cellebrite DI Ltd Q3FY26 Results: Reporting date confirmed for Nov 12

Cellebrite DI Ltd will report Q3 2026 results on November 12, 2026. Conference call scheduled for 8:30 am ET same day. Only the analyst call-in number has been updated from prior announcements.

Three law firms investigate Cellebrite over Q2 ARR miss and CEO exit

Kaplan Fox & Kilsheimer LLP has joined SBS Law and Pomerantz LLP in investigating Cellebrite DI Ltd. for potential securities violations. Cellebrite's Q2 ARR of $507.8 million missed the lower end of its prior guidance range of $510 million to $513 million. The company cut full-year ARR guidance by roughly $15 million at the midpoint, citing a foreign entity permit requirement on cloud technology. CEO Tom Hogan was replaced by Shiv Ramji effective immediately alongside the financial disclosures. Cellebrite shares fell $4.45 per share, or 29%, to close at $10.80 on August 13, 2026.

Cellebrite CTO Chris Wade to Lead Cellebrite Labs

Chris Wade, CTO, takes over Cellebrite Labs, integrating it into the Innovation Hub. Move aims to sharpen focus on mobile access, extraction, and decoding technology. Company commits additional AI resources, infrastructure, and talent to the unit. Structural change follows acquisition of Corellium and Wade's subsequent hiring. Virtual Fireside Chat scheduled for September 14, 2026, to discuss AI strategy.

Kaplan Fox probes Cellebrite after Q2 ARR miss and CEO switch

Kaplan Fox investigates Cellebrite for potential securities violations following Q2 earnings miss. Q2 ARR of $507.8 million missed the lower bound of $510-$513 million guidance range. Full-year ARR guidance cut by approximately $15 million amid regulatory delays. CEO Tom Hogan replaced by Shiv Ramji effective immediately on August 13, 2026. Stock price fell 29% to $10.80 per share on the day of the announcement.

Cellebrite launches C-TEK portable kit for military field intelligence

Cellebrite launches C-TEK, a ruggedized mobile forensics kit for military use. Kit enables real-time data extraction from phones, drones and media in the field. Designed for disconnected environments where lab analysis delays are critical. Part of broader roadmap including portable Pathfinder analytics and AI tools.

Levi & Korsinsky probes Cellebrite DI after 30% stock drop on missed targets

Levi & Korsinsky investigates Cellebrite DI for potential securities fraud. CLBT stock fell over 30% after Q2 FY26 results missed consensus targets. Company cut full-year ARR guidance from $567-573 million to $550-560 million. Q2 ARR of $507.8 million missed the $510 million floor projection. Shiven Ramji completes planned succession as new CEO.